{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:10:12Z","timestamp":1789470612545,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As a member of the Janus kinase (JAK) family, which includes JAK1, JAK2 and JAK3, tyrosine kinase 2 (TYK2) plays an important role in signal transduction and immune system regulation. Moreover, it is also involved in the development of many types of inflammatory and autoimmune diseases, such as psoriasis and systemic lupus erythematosus (SLE). TYK2 is an attractive therapeutic target, and selective inhibition of TYK2 over other JAK family members is critical for the development of TYK2 small molecule inhibitors. However, targeting the catalytic region of the TYK2 ATP-binding site is a major challenge due to the high structural homology between the catalytic regions of the JAK family proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we developed a novel small molecule inhibitor (QL-1200186) by targeting the pseudokinase regulatory domain (Janus homology 2, JH2) of the TYK2 protein. The binding sites of QL-1200186 were predicted and screened by molecular docking. The inhibitory effects on IFN\u03b1, IL-12 and IL-23 signaling were tested in cell lines, human peripheral blood cells and human whole blood. The pharmacokinetic (PK) and pharmacodynamic properties of QL-1200186 were verified in mice. QL-1200186 showed high affinity for TYK2 JH2 and had no apparent selectivity for the TYK2 and JAK homologous kinase domains; these effects were demonstrated using biochemical binding, signaling pathway transduction (JAK1\/2\/3) and off-target effect assays. More importantly, we revealed that QL-1200186 was functionally comparable and selectivity superior to two clinical-stage TYK2 inhibitors (BMS-986165 and NDI-034858) in vitro. In the PK studies, QL-1200186 exhibited excellent exposure, high bioavailability and low clearance rates in mice. Oral administration of QL-1200186 dose-dependently inhibited interferon-\u03b3 (IFN\u03b3) production after interleukin-12 (IL-12) challenge and significantly ameliorated skin lesions in psoriatic mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that QL-1200186 is a highly selective and potent inhibitor of TYK2. QL-1200186 could be an appealing clinical drug candidate for the treatment of psoriasis and other autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-023-01299-7","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:03:51Z","timestamp":1697432631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways"],"prefix":"10.1186","volume":"21","author":[{"given":"Celia X.-J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"Suppl 1","key":"1299_CR1","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O\u2019Shea JJ. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019;58(Suppl 1):i4\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1299_CR2","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27(12):1984\u20132009.","journal-title":"Protein Sci"},{"issue":"4","key":"1299_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374\u201384.","journal-title":"Nat Immunol"},{"issue":"12","key":"1299_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"10302","key":"1299_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803\u201316.","journal-title":"Lancet"},{"key":"1299_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106359","volume":"183","author":"M Benucci","year":"2022","unstructured":"Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V, Gobbi FL, Sarzi-Puttini P. Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted. Pharmacol Res. 2022;183: 106359.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1299_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0092-8674(92)90105-L","volume":"70","author":"L Velazquez","year":"1992","unstructured":"Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha\/beta signaling pathway. Cell. 1992;70(2):313\u201322.","journal-title":"Cell"},{"issue":"5","key":"1299_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/ni910","volume":"4","author":"M Karaghiosoff","year":"2003","unstructured":"Karaghiosoff M, Steinborn R, Kovarik P, Kriegshauser G, Baccarini M, Donabauer B, Reichart U, Kolbe T, Bogdan C, Leanderson T, et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol. 2003;4(5):471\u20137.","journal-title":"Nat Immunol"},{"issue":"4","key":"1299_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","volume":"13","author":"M Karaghiosoff","year":"2000","unstructured":"Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity. 2000;13(4):549\u201360.","journal-title":"Immunity"},{"issue":"4","key":"1299_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","volume":"13","author":"K Shimoda","year":"2000","unstructured":"Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, Yamashita M, Numata A, Takase K, Kobayashi S, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity. 2000;13(4):561\u201371.","journal-title":"Immunity"},{"issue":"1","key":"1299_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4049\/jimmunol.1003244","volume":"187","author":"M Ishizaki","year":"2011","unstructured":"Ishizaki M, Akimoto T, Muromoto R, Yokoyama M, Ohshiro Y, Sekine Y, Maeda H, Shimoda K, Oritani K, Matsuda T. Involvement of tyrosine kinase-2 in both the IL-12\/Th1 and IL-23\/Th17 axes in vivo. J Immunol. 2011;187(1):181\u20139.","journal-title":"J Immunol"},{"issue":"8","key":"1299_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1136\/annrheumdis-2021-221754","volume":"81","author":"S Saevarsdottir","year":"2022","unstructured":"Saevarsdottir S, Stefansdottir L, Sulem P, Thorleifsson G, Ferkingstad E, Rutsdottir G, Glintborg B, Westerlind H, Grondal G, Loft IC, et al. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Ann Rheum Dis. 2022;81(8):1085\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1299_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/intimm\/dxr057","volume":"23","author":"M Ishizaki","year":"2011","unstructured":"Ishizaki M, Muromoto R, Akimoto T, Ohshiro Y, Takahashi M, Sekine Y, Maeda H, Shimoda K, Oritani K, Matsuda T. Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Int Immunol. 2011;23(9):575\u201382.","journal-title":"Int Immunol"},{"issue":"11","key":"1299_CR14","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.4049\/jimmunol.0902740","volume":"183","author":"A Oyamada","year":"2009","unstructured":"Oyamada A, Ikebe H, Itsumi M, Saiwai H, Okada S, Shimoda K, Iwakura Y, Nakayama KI, Iwamoto Y, Yoshikai Y, et al. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J Immunol. 2009;183(11):7539\u201346.","journal-title":"J Immunol"},{"issue":"13","key":"1299_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2217\/imt-2021-0096","volume":"13","author":"M Gonciarz","year":"2021","unstructured":"Gonciarz M, Pawlak-Bus K, Leszczynski P, Owczarek W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy. 2021;13(13):1135\u201350.","journal-title":"Immunotherapy"},{"issue":"363","key":"1299_CR16","doi-asserted-by":"publisher","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, Barber T, Kaur G, Kuttikkatte SB, Leach OA, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1299_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","volume":"29","author":"X He","year":"2019","unstructured":"He X, Chen X, Zhang H, Xie T, Ye XY. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015\u20132018). Expert Opin Ther Pat. 2019;29(2):137\u201349.","journal-title":"Expert Opin Ther Pat"},{"issue":"45","key":"1299_CR18","doi-asserted-by":"publisher","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","volume":"290","author":"X Min","year":"2015","unstructured":"Min X, Ungureanu D, Maxwell S, Hammaren H, Thibault S, Hillert EK, Ayres M, Greenfield B, Eksterowicz J, Gabel C, et al. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2). J Biol Chem. 2015;290(45):27261\u201370.","journal-title":"J Biol Chem"},{"issue":"502","key":"1299_CR19","doi-asserted-by":"publisher","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736.","journal-title":"Sci Transl Med"},{"issue":"Pt 3","key":"1299_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/brain\/awr010","volume":"134","author":"N Couturier","year":"2011","unstructured":"Couturier N, Bucciarelli F, Nurtdinov RN, Debouverie M, Lebrun-Frenay C, Defer G, Moreau T, Confavreux C, Vukusic S, Cournu-Rebeix I, et al. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain. 2011;134(Pt 3):693\u2013703.","journal-title":"Brain"},{"issue":"4","key":"1299_CR21","doi-asserted-by":"publisher","first-page":"e0122271","DOI":"10.1371\/journal.pone.0122271","volume":"10","author":"D Diogo","year":"2015","unstructured":"Diogo D, Bastarache L, Liao KP, Graham RR, Fulton RS, Greenberg JD, Eyre S, Bowes J, Cui J, Lee A, et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE. 2015;10(4):e0122271.","journal-title":"PLoS ONE"},{"issue":"8","key":"1299_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1136\/annrheumdis-2015-208154","volume":"75","author":"E Lopez-Isac","year":"2016","unstructured":"Lopez-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeon CP, Carreira P, Ortego-Centeno N, de Garciala Pena P, Spanish Scleroderma G, et al. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann Rheum Dis. 2016;75(8):1521\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1299_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Thaci D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR24","doi-asserted-by":"publisher","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","volume":"66","author":"S Leit","year":"2023","unstructured":"Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, Blanchette H, Boyles NA, Cartwright M, Collis A, et al. Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279. J Med Chem. 2023;66:10473\u201396.","journal-title":"J Med Chem"},{"key":"1299_CR25","unstructured":"Chung TDY, Terry DB, Smith LH. In Vitro and In Vivo Assessment of ADME and PK Properties During Lead Selection and Lead Optimization - Guidelines, Benchmarks and Rules of Thumb. In: Assay Guidance Manual. edn. Edited by Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C, Baell J, Chung TDY, Coussens NP, Dahlin JL et al. Bethesda (MD). 2004."},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"110434","DOI":"10.1016\/j.intimp.2023.110434","volume":"121","author":"L Deng","year":"2023","unstructured":"Deng L, Wan L, Liao T, Wang L, Wang J, Wu X, Shi J. Recent progress on tyrosine kinase 2 JH2 inhibitors. Int Immunopharmacol. 2023;121:110434.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1299_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","volume":"59","author":"J Jiang","year":"2020","unstructured":"Jiang J, Zhao M, Chang C, Wu H, Lu Q. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. Clin Rev Allergy Immunol. 2020;59(2):248\u201372.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"1299_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","volume":"64","author":"C Liu","year":"2021","unstructured":"Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski JS, Khan J, Ruzanov M, Strnad J, Zupa-Fernandez A, et al. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. J Med Chem. 2021;64(1):677\u201394.","journal-title":"J Med Chem"},{"issue":"8","key":"1299_CR29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","volume":"44","author":"J Setyawan","year":"2021","unstructured":"Setyawan J, Azimi N, Strand V, Yarur A, Fridman M. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010\u20132019. Drug Saf. 2021;44(8):889\u201397.","journal-title":"Drug Saf"},{"issue":"1","key":"1299_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/COC.0000000000000023","volume":"39","author":"MR Green","year":"2016","unstructured":"Green MR, Newton MD, Fancher KM. Off-Target Effects of BCR-ABL and JAK2 Inhibitors. Am J Clin Oncol. 2016;39(1):76\u201384.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"1299_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ph12010037","volume":"12","author":"A Mayence","year":"2019","unstructured":"Mayence A, VandenEynde JJ. Baricitinib: A 2018 Novel FDA-approved small molecule inhibiting Janus kinases. Pharmaceuticals (Basel). 2019;12(1):37.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"1299_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"1299_CR33","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","volume":"204","author":"M Gadina","year":"2020","unstructured":"Gadina M, Chisolm DA, Philips RL, McInness IB, Changelian PS, O\u2019Shea JJ. Translating JAKs to Jakinibs. J Immunol. 2020;204(8):2011\u201320.","journal-title":"J Immunol"},{"issue":"17","key":"1299_CR34","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM. Deucravacitinib: First Approval. Drugs. 2022;82(17):1671\u20139.","journal-title":"Drugs"},{"issue":"22","key":"1299_CR35","doi-asserted-by":"publisher","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","volume":"63","author":"BS Gerstenberger","year":"2020","unstructured":"Gerstenberger BS, Ambler C, Arnold EP, Banker ME, Brown MF, Clark JD, Dermenci A, Dowty ME, Fensome A, Fish S, et al. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020;63(22):13561\u201377.","journal-title":"J Med Chem"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-023-01299-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T06:12:41Z","timestamp":1700547161000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-023-01299-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1186\/s12964-023-01299-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2914960\/v1","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Animal Care and Use Committee of Qilu Pharmaceuticals. Samples of peripheral blood were taken from healthy volunteers who provided written informed consent in accordance with the guidelines and regulations set by Qilu Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}